Is there any domestically produced bimetinib/bemetinib?

Binimetinib is a new oral targeted anticancer drug. According to the latest drug registration and marketing information, although the original drug of bimetinib has been approved for marketing in many countries such as Europe, the United States, and Japan, it has not yet been officially approved for sale in mainland China. Therefore, there is currently no domestic version of bimetinib on the market, and no domestic company has obtained a generic license for this drug. In other words, bimetinib is currently in a state of “no domestic production, no imitation, and can only be purchased overseas” in China.

Because bimetinib is a highly selectiveMEK inhibitor and an innovative targeted drug, its development and production require complex molecular synthesis and rigorous clinical verification. This is also an important reason why there are currently no generic drugs in China. At present, domestic pharmaceutical companies mainly focus on the development of BRAF inhibitors or other signaling pathway-related drugs, while the development of inhibitors for the MEK pathway is relatively small. However, with the rapid development of the domestic medical field, many pharmaceutical companies are actively conducting clinical research on MEK target drugs, so there may be breakthroughs in localization in the future.

In overseas markets, bimetinib is mostly used to treat advanced melanoma with BRAF V600E or V600K mutations. It is often used in combination with the BRAF inhibitor Encorafenib. This combination is considered by the international oncology community to be a "highly effective and capable of delaying drug resistance" treatment combination, making bimetinib one of the most representative MEK inhibitors in the global market. At present, both the European and American versions of bimetinib have been commercially sold, but the price is generally higher, with each box selling for tens of thousands of yuan.

For domestic patients, if they need to use bimetinib, they can only obtain it through formal cross-border medical institutions or overseas drug purchase channels. It is worth noting that since the drug has not yet been registered with the National Food and Drug Administration (NMPA) of China, patients should carefully choose formal channels when purchasing drugs and avoid purchasing preparations from unknown sources.

Reference materials:https://go.drugbank.com/drugs/DB11967